[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"coughing\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:coughing":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,50,101,127,162,202],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":30,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100617211","acupressure-for-cough-in-lung-cancer-survivors-100617211",false,"NCT07315672","Acupressure for Cough in Lung Cancer Survivors","Acupressure for Cough in Lung Cancer Survivors: A Randomized Controlled Trial","Inclusion Criteria:\n\n* be at least 18 years of age;\n* have a diagnosis of LC at any stage and of any pathological type;\n* have a cough symptom rating ≥3 on a 0 to 10 numeric rating scale within 7 days preceding enrollment;\n* can perform acupressure independently in daily activities;\n* be able to read Chinese and communicate in Cantonese or Mandarin;\n* be able to provide informed consent.\n\nExclusion Criteria:\n\n* have unstable chronic diseases other than LC;\n* have received acupressure or acupuncture within the three months preceding study enrollment;\n* have serious illnesses or other conditions that prevent the participants from following the intervention protocols;\n* have a life expectancy of less than 3 months;\n* Be currently participating in other research programs that may affect the outcomes under investigation.","ALL","18 Years",{"count":19,"type":20},80,"ESTIMATED","INTERVENTIONAL",[23],"NA","The goal of this randomized controlled trial is to examine the effect of an acupressure intervention in alleviating cough and reducing co-occurring symptoms (dyspnea, cough, and fatigue) in patients with lung cancer.\n\nThe hypotheses are:\n\n1. Acupressure can alleviate cough in lung cancer survivors;\n2. Acupressure can reduce a cough-related symptom cluster (dyspnea-cough-fatigue) experienced by lung cancer survivors;\n3. Acupressure can reduce the symptom burden and improve the health-related quality of life and functional capacity of lung cancer survivors experiencing cough.\n\nParticipants will:\n\nReceive acupressure for 8 weeks or receive an education booklet; Keep a diary of their acupressure practice and symptoms; Be assessed at baseline (T0), early intervention (T1), post-intervention (T2), and 8 weeks after the intervention period (T3).",[26,27,28,29],"Lung Cancer (Diagnosis)","Acupressure","Coughing","Symptom Cluster",[27,31,32,33,29,34,35,36],"Cough","Lung Cancer","Dyspnea","Symptom Burden","Fatigue","Quality of Life","RECRUITING","2026-05-20",{"date":40,"type":41},"2026-05-22","ACTUAL",{"date":43,"type":41},"2026-03-09",{"date":45,"type":20},"2027-02",{"name":47,"class":48},"The University of Hong Kong","OTHER",2,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":58,"minAge":59,"maxAge":4,"enrollmentInfo":60,"targetDuration":4,"studyType":21,"phases":62,"briefSummary":63,"conditions":64,"keywords":81,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":100},"100636706","improved-child-nutrition-and-development-through-social-transfers-100636706","NCT07569172","Improved Child Nutrition and Development Through Social Transfers","Taabo Enhanced Nutrition and Development Through Economic Rewards","TENDER","Inclusion Criteria:\n\n1. Are enrolled in the Taabo multigenerational birth cohort (MGC)\n2. Completed the postpartum interview of the Taabo MGC\n3. Have a child who is within two weeks of their 12-month birthday,\n4. are breastfeeding at time of recruitment,\n5. live in the Taabo HDSS, Côte d'Ivoire\n6. have no illnesses that contraindicates breastfeeding,\n7. had a healthy singleton infant with a birth weight of at least 2500 grams, and\n8. agree to participate and sign an informed consent; if underage (12-17 years), a legal representative will also have to agree to sign the informed consent\n\nExclusion Criteria:\n\n1. Plans to move permanently outside study area\n2. Has a medical, intellectual or psychological disability\n3. Contraindication for breastfeeding\n4. Children born with \\\u003C 2500 grams","FEMALE","12 Years",{"count":61,"type":20},1040,[23],"The goal of this clinical trial is to learn if a conditional social transfer works to improve rates of complementary breastfeeding. It will also learn about the impacts of social transfers on maternal and child health and development. The main questions it aims to answer are:\n\n* Does the social transfer increase complementary breastfeeding rates at 24-months postpartum?\n* Does the social transfer increase complementary breastfeeding duration?\n* Does the social transfer impact child health and development?\n* Does the social transfer impact maternal physical and mental health?\n\nResearchers will compare a conditional social transfer to a control group that only receives education about breastfeeding recommendations to see if a conditional social transfers works to increase complementary breastfeeding.\n\nParticipants will:\n\nReceive a pamphlet explaining the current recommendations of breastfeeding Receive instructions that if they meet the recommendation to breastfeed until 24-months postpartum they receive a social transfer or receive no additional information Complete home visits at 12- and 24-months postpartum Complete detailed questionnaire",[65,66,67,68,69,70,71,72,73,74,75,76,77,28,78,79,80],"Breastfeeding","Breastfeeding Education","Breastfeeding Duration","Breastfeeding Continuation","Child Growth","Stress","Infectious Diseases","Anemia","Child Development","Weight Loss","Blood Pressure","Mental Health","Diarrhea","Eczema","Allergies","Antibiotic Use",[82,83,84,85,86,87,88,89],"breastfeeding","cash transfer","child health","maternal health","mental health","child growth","child development","education","NOT_YET_RECRUITING","2026-04-28",{"date":93,"type":41},"2026-05-06",{"date":95,"type":20},"2026-06-01",{"date":97,"type":20},"2028-02-28",{"name":99,"class":48},"Swiss Tropical & Public Health Institute",1,{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":4,"eligibilityCriteria":107,"healthyVolunteers":108,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":109,"targetDuration":4,"studyType":21,"phases":111,"briefSummary":112,"conditions":113,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":100},"100614569","mindfulness-oriented-respiratory-distress-symptom-intervention-for-lung-cancer-100614569","NCT07281300","Mindfulness-Oriented Respiratory Distress Symptom Intervention for Lung Cancer","Mindfulness-Oriented Respiratory Distress Symptom Intervention for Patients With Lung Cancer: A Feasibility Randomized Controlled Trial","Inclusion Criteria:\n\n* HK patients who can understand Cantonese, aged 18 years or older;\n* A confirmed diagnosis of an intrathoracic malignancy, including small cell lung cancer, non-small cell lung cancer, or mesothelioma; at any stage of cancer treatment or palliative care;\n* Self-reported impact on daily life from at least two of the three symptoms, where one symptom is breathlessness;\n* Stability of COPD, if present;\n* WHO Performance Status of 0-2;\n* fMRI can be conducted;\n* Expected lifespan of more than six months.\n\nExclusion Criteria:\n\n* Cognitive impairments, severe psychotic symptoms, or other medical conditions that might hinder participation;\n* Participating in mindfulness or other psychological support interventions or symptom management interventions.",true,{"count":110,"type":20},64,[23],"Lung cancer is the leading cause of cancer mortality, posing a critical public health challenge in both Hong Kong and global populations. Patients with lung cancer frequently experience a distressing symptom cluster characterized by breathlessness-driven respiratory distress, accompanied by persistent cough and fatigue, which collectively impose a substantial disease burden. While our research team leader previously developed and validated a multi-component Respiratory Distress Symptom Intervention (RDSI) in England, demonstrating clinical efficacy for lung cancer management, its impact on psychological distress (anxiety and depression) proved limited. This limitation may reflect insufficient integration of psychological components, a crucial consideration given the well-established bidirectional relationship between respiratory symptoms and psychological distress. Emerging evidence indicates that mindfulness interventions provide dual therapeutic benefits by improving patient adherence and effectively addressing both physical symptoms, such as breathlessness and fatigue, as well as psychological distress, including anxiety and depression. Meanwhile, current evaluation methodologies have mainly focused on behavioral data collection, such as self-reported questionnaires, to reflect the effect before and after the intervention. Neuroimaging data can help understand the brain mechanisms underlying breathlessness and elucidate the effectiveness of interventions, thereby improving intervention strategies.",[29,114,28,115,116,117],"Breathlessness","Fatigue Symptom","Lung Cancer Patients","Brain Activity","2026-04-14",{"date":120,"type":41},"2026-04-17",{"date":122,"type":41},"2025-08-12",{"date":124,"type":20},"2027-07-30",{"name":126,"class":48},"The Hong Kong Polytechnic University",{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":131,"acronym":132,"eligibilityCriteria":133,"healthyVolunteers":11,"sex":16,"minAge":134,"maxAge":4,"enrollmentInfo":135,"targetDuration":4,"studyType":21,"phases":137,"briefSummary":138,"conditions":139,"keywords":146,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":161},"100515299","validation-of-the-c-mo-system---cough-monitoring-100515299","NCT05989698","Validation of the C-mo System - Cough Monitoring","C-mo_01","Inclusion Criteria:\n\n* Patients aged 2 years or older;\n* Patients with symptoms\u002Fcomplaints of cough;\n* Signed Informed Consent (age ≥ 18 years), signed Informed Consent from the parents\u002Flegal representative and the patient (16 and 17 years), or signed Informed Assent and Consent (5 years ≤ age ≤ 15 years).\n\nExclusion Criteria:\n\n* Presence of musculoskeletal (e.g., severe scoliosis), neurological (e.g., post stroke), cardiac (e.g., unstable angina), cognitive (e.g., dementia) changes, or other significant conditions that hinder the participants from collaborating in the collection of data.\n* Damaged\u002Fweakened skin at the C-mo wearable device's placement area (epigastric region).\n* Absence of Informed Consent and\u002For Assent, as applicable.","2 Years",{"count":136,"type":20},300,[23],"The goal of this clinical study is to validate C-mo System's ability to automatically detect and characterise cough, in patients over 2 years old with cough as a key or refractory symptom.\n\nThe main questions it aims to answer are:\n\n1. Can C-mo System detect cough events? (automatic cough detection)\n2. Can C-mo System characterise cough events? (calculation of cough intensity, identification of cough type and presence of wheeze in detected coughs)\n\nParticipants will be asked to:\n\n* Wear the C-mo Wearable device for 24 hours (1 day);\n* Complete a diary with relevant activities throughout the monitoring period;\n* Fill-out questionnaires related to coughing frequency and intensity, usability of the device, and impact of cough on quality of life.",[31,140,141,142,143,144,145,28],"Asthma","Chronic Obstructive Pulmonary Disease","Gastro Esophageal Reflux","Idiopathic Pulmonary Fibrosis","Cough Frequency","Cough Severity",[147,148,149,150],"Cough monitoring","Cough detection","Cough assessment","C-mo","2026-04-02",{"date":153,"type":41},"2026-04-08",{"date":155,"type":41},"2023-12-11",{"date":157,"type":20},"2026-09",{"name":159,"class":160},"Cough Monitoring Medical Solutions","INDUSTRY",8,{"id":163,"slug":164,"hasResults":11,"nctId":165,"briefTitle":166,"officialTitle":167,"acronym":168,"eligibilityCriteria":169,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":170,"targetDuration":4,"studyType":21,"phases":172,"briefSummary":173,"conditions":174,"keywords":184,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":193,"lastUpdatePostDateStruct":194,"startDateStruct":196,"completionDateStruct":198,"leadSponsor":200,"locationsCount":100},"100566450","efficiency-of-the-medidux-smartphone-app-for-demission-management-in-patients-medicated-in-acute-admission-unit-aau-100566450","NCT06655337","Efficiency of the \"Medidux\" Smartphone App for Demission Management in Patients Medicated in Acute Admission Unit (AAU)","Efficiency of the \"Medidux\" Smartphone App for Demission Management in Patients Medicated in Acute Admission Unit (AAU): a Randomized Controlled Trial.","EffiDux","Inclusion Criteria:\n\n* Signed Informed Consent Form (ICF)\n* Age ≥ 18 years\n* (Self-)admission to the involved Acute Admissions Unit (AAU)\n* \"Lead symptom\" identified as coughing, back pain or abdominal discomfort\n* Participant within ESI triage system group 4 (standard) and 5 (non-urgent)\n* German-speaking\n* Ownership of a smartphone or other mobile device with iOS or Android operating system\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years\n* Participant whose compliance to the study's protocol, e.g. due to mental health problems, physical problems, or the private life situation, can be justifiably doubted\n* Participant with insufficient knowledge about the use of a smartphone or other mobile device with iOS or Android operating system\n* Participant already using or planning to use another comparable electronic patient-reported symptom monitoring system (e.g. CANKADO) during this trial",{"count":171,"type":20},417,[23],"The goal of this clinical trial is to evaluate whether the use of the medidux™ smartphone app can optimize post-discharge management for patients admitted to Acute Admission Units (AAU) with non-urgent health complaints. This trial includes adult patients (age ≥ 18) in Emergency Severity Index (ESI) triage system groups 4 (standard) or 5 (non-urgent), presenting with primary symptoms such as cough, back pain, or abdominal discomfort.\n\nThe main question it aims to answer is:\n\nCan the medidux™ app reduce the incidence of AAU readmissions, emergency hospitalizations, or consultations with other medical providers within 7 days after initial admission?\n\nResearchers will compare participants using the medidux™ app (intervention arm) with those receiving standard care (control arm) to observe potential differences in the rates of readmissions, emergency hospitalizations, and medical consultations.\n\nParticipants will:\n\n* use the medidux™ app to monitor their symptoms and vital parameters for 7 days after discharge (intervention arm).\n* receive follow-up consultations at day 7 and at day 28 to assess symptom progression and any healthcare interactions (both arms).",[175,176,28,177,178,179,180,181,182,183],"Acute Disease","Acute Hospitalization","Back Pain","Abdominal Pain (AP)","Patient Discharge","Patient Readmission","Mobile Health Apps","Mobile Health Technology (mHealth)","Patient Reported Outcome (PRO)",[175,179,180,28,177,185,186,187,188,189,190,191,192],"Abdominal Pain","Mobile Health Applications","Remote Monitoring","Post-discharge Care","Symptom Monitoring","Health Behaviour","Telemedicine","Randomized Controlled Trial","2025-09-29",{"date":195,"type":41},"2025-10-03",{"date":197,"type":41},"2025-09-28",{"date":199,"type":20},"2027-03-28",{"name":201,"class":160},"Mobile Health AG",{"id":203,"slug":204,"hasResults":11,"nctId":205,"briefTitle":206,"officialTitle":207,"acronym":4,"eligibilityCriteria":208,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":209,"targetDuration":4,"studyType":21,"phases":211,"briefSummary":213,"conditions":214,"keywords":217,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":222,"lastUpdatePostDateStruct":223,"startDateStruct":225,"completionDateStruct":227,"leadSponsor":229,"locationsCount":100},"100564872","early-phase-1-efficacy-of-intramuscular-steroid-injection-for-chronic-cough-100564872","NCT06634823","Efficacy of Intramuscular Steroid Injection for Chronic Cough.","Prospective Placebo-Controlled Trial of Intramuscular Steroid Administration for the Treatment of Unexplained Chronic Cough","Inclusion Criteria:\n\n* History consistent with chronic unexplained or refractory cough\n* Age ≥ 18\n\nExclusion Criteria:\n\n* Current smokers\n* Uncontrolled diabetes (A1c\\>7%)\n* Patients on ACE inhibitors or Angiotensin II receptor blockers (ARBs)\n* Abnormal pulmonary function testing (PFTs) since start of the cough\n* Patients with uncontrolled obstructive sleep apnea\n* Abnormal chest X-ray within past 6 months\n* Uncontrolled reflux\n* Prior superior laryngeal nerve injection\n* Current neuromodulating medication use for chronic cough\\*",{"count":210,"type":20},40,[212],"EARLY_PHASE1","The primary goal of this study is to test the hypothesis that injecting steroid intramuscularly is an effective treatment for unexplained chronic cough. This will be achieved through the design of a prospective, placebo-controlled, single-blind, randomized clinical trial in which one group of patients will undergo a steroid injection into the deltoid muscle and the second group will undergo a placebo injection into the deltoid muscle. Data to determine if a clinically significant difference exists between the outcomes of the two groups will be measured by a dichotomous yes\u002Fno response to improvement, the Leicester Cough Questionnaire, and a visual analogue scale for symptom severity. This will provide the answer to the general question of whether or not the intramuscular injections are clinically effective for patients with unexplained chronic cough. Furthermore, any adverse reactions will be thoroughly documented. If this hypothesized treatment is proven effective, this can greatly improve the care of chronic cough patients by allowing for an evidence-based treatment option and a treatment option that may improve access to care. While the superior laryngeal nerve (SLN) injection is typically performed by fellowship trained laryngologists, intramuscular injections could be more widely utilized by general otolaryngologists or providers in other fields of medicine.",[215,216,28],"Chronic Cough (CC)","Laryngeal Disease",[218,219,220,221],"Throat","Chronic cough","Neurogenic cough","Unexplained cough","2025-07-09",{"date":224,"type":41},"2025-07-14",{"date":226,"type":41},"2024-12-02",{"date":228,"type":20},"2026-06-30",{"name":230,"class":48},"Medical University of South Carolina"]